PTC THERAPEUTICS, INC. PTCT
We are a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. We are advancing a robust and diversified pipeline of transformative medicines as part of our mission to provide access to best-in-class treatments for patients with unmet medical needs. Our strategy is to leverage our scientific expertise and global commercial infrastructure to optimize value for our patients and other stakeholders.
We have a diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The disclosure below summarizes the status of our significant commercial products and clinical-stage programs as of the date of this report, including those with our strategic partners:
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.73B | $806.8M | $937.8M | $698.8M | $538.6M | $380.8M | $307.0M | $264.7M | $194.4M | $82.7M |
| Cost of revenue | — | — | — | — | — | — | $12.1M | $12.7M | $4.6M | $0 |
| Gross profit | — | — | — | — | — | — | $294.8M | $252.1M | $189.8M | $82.7M |
| R&D | $455.2M | $534.5M | $666.6M | $651.5M | $540.7M | $477.6M | $257.5M | $172.0M | $117.5M | $117.6M |
| SG&A | $347.1M | $300.9M | $332.5M | $326.0M | $285.8M | $245.2M | $202.5M | $153.5M | $121.3M | $97.1M |
| Total operating expenses | $863.7M | $1.11B | $1.38B | $1.15B | $913.0M | $812.5M | $548.1M | $380.4M | $258.7M | $214.8M |
| Operating income | $866.9M | -$302.6M | -$439.5M | -$447.4M | -$374.4M | -$431.8M | -$241.2M | -$115.7M | -$64.3M | -$132.1M |
| Pre-tax income | $696.6M | -$363.1M | -$696.1M | -$587.5M | -$518.3M | -$402.9M | -$239.9M | -$128.1M | -$77.7M | -$141.5M |
| Income tax | $14.0M | $176.0K | $69.5M | $28.5M | $5.6M | $35.2M | $11.7M | $29.0K | $1.3M | $569.0K |
| Net income | $683.0M | -$363.3M | -$626.6M | -$559.0M | -$523.9M | -$438.2M | -$251.6M | -$128.1M | -$79.0M | -$142.1M |
| EPS, basic | 8.58 | -4.73 | -8.37 | -7.79 | -7.43 | -6.64 | -4.27 | -2.75 | -2.02 | — |
| EPS, diluted | 7.78 | -4.73 | -8.37 | -7.79 | -7.43 | -6.64 | -4.27 | -2.75 | -2.02 | -4.17 |
| Shares, diluted (wtd. avg.) | $88.3M | $76.8M | $74.8M | $71.7M | $70.5M | $66.0M | $58.9M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $984.6M | $779.7M | $610.3M | $295.9M | $197.2M | $216.3M | $295.5M | $169.5M | $111.8M | $58.3M |
| Short-term investments | $960.7M | $360.0M | $282.7M | $130.9M | $583.7M | $894.8M | $398.5M | $58.1M | $79.5M | $173.3M |
| Receivables | $181.6M | $158.6M | $160.8M | $155.6M | $110.5M | $69.9M | $55.5M | $67.9M | $40.4M | $24.9M |
| Inventory | $79.6M | $23.2M | $30.6M | $21.8M | $15.9M | $18.7M | $19.3M | $16.1M | $10.8M | $0 |
| Total current assets | $2.27B | $1.37B | $1.22B | $693.8M | $954.4M | $1.23B | $779.3M | $320.9M | $249.1M | $261.3M |
| Property, plant and equipment | $55.4M | $61.0M | $87.1M | $72.6M | $52.6M | $33.8M | $21.5M | $12.7M | $8.4M | $7.4M |
| Goodwill | $82.3M | $82.3M | $82.3M | $82.3M | $82.3M | $82.3M | $82.3M | $82.3M | $0 | — |
| Other intangibles | $388.8M | $118.8M | $379.5M | $705.9M | $724.8M | $715.3M | $710.5M | $701.0M | $133.0M | $0 |
| Total assets | $2.90B | $1.71B | $1.90B | $1.71B | $1.94B | $2.21B | $1.62B | $1.12B | $391.7M | $269.3M |
| Accounts payable | $45.5M | $17.3M | $6.0M | $27.3M | $23.0M | $18.7M | $10.3M | $6.0M | $15.3M | $6.3M |
| Short-term debt | $286.6M | — | — | — | $149.5M | — | $20.0M | $11.7M | $0 | — |
| Total current liabilities | $968.4M | $581.0M | $603.1M | $406.2M | $509.3M | $277.3M | $235.9M | $166.8M | $82.0M | $49.6M |
| Long-term debt | — | $285.4M | $284.2M | $571.7M | $281.9M | $309.1M | $293.9M | $141.3M | $145.0M | $98.2M |
| Total liabilities | $3.10B | $2.80B | $2.71B | $2.05B | $1.94B | $1.73B | $1.03B | $768.5M | $235.2M | $149.8M |
| Retained earnings | -$2.96B | -$3.65B | -$3.28B | -$2.66B | -$2.10B | -$1.63B | -$1.19B | -$938.9M | -$814.1M | -$735.1M |
| Total equity | -$205.3M | -$1.10B | -$818.6M | -$347.1M | $1.4M | $482.0M | $594.3M | $350.7M | $156.4M | $119.6M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $711.2M | -$107.7M | -$158.4M | -$356.7M | -$251.3M | -$194.1M | -$98.6M | -$27.6M | -$10.1M | -$103.6M |
| Depreciation and amortisation | $38.8M | $75.7M | $236.6M | $128.8M | $64.1M | $43.5M | $32.2M | $26.1M | $17.7M | $3.3M |
| Stock-based compensation | $74.5M | $74.6M | $101.6M | $110.3M | $103.5M | $70.3M | $42.1M | $33.3M | $30.6M | $35.0M |
| Capital expenditure | $8.9M | $6.5M | $28.4M | $32.0M | $28.2M | $17.8M | $13.8M | $7.1M | $3.1M | $1.8M |
| Investing cash flow | -$862.0M | $44.2M | -$176.7M | $290.2M | $219.2M | -$561.5M | -$387.2M | -$42.6M | $13.1M | $104.5M |
| Financing cash flow | $331.1M | $255.9M | $646.4M | $168.0M | $20.9M | $668.7M | $613.2M | $131.6M | $44.2M | $968.0K |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-045528.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |